AI stands to make some massive impacts in MS, often in levelling up the standard and consistency of the care we receive. I am on the board of a UK based trial examining the icobrainms tool in looking at MRI. This article is about a similar wider reaching project in Europe. The TL;DR version is as follows: ⚫ As MS presents with a highly variable course and diverse patient experiences, traditional treatment optimization approaches often fall short. This calls for a shift towards a more pro-active, data-driven and personalized medicine approach that could potentially improve patient outcomes for pwMS. ⚫ The project will develop, validate and seek regulatory approval for an AI-driven clinical decision-support platform, which offers the MS care team a holistic view of the patient through the visualization of all relevant patient data and the prognosis on the expected disease trajectories under different treatment regimens. ⚫ Prognostic models of clinical progression and treatment response will be developed based on a vast and diverse dataset combining clinical trial and real-world data, in order to develop AI-based prediction models that are applicable in real-world clinical settings. The full article is here: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1446748/full